ANI Pharmaceuticals reported a robust second quarter 2026, with revenue and adjusted earnings exceeding analyst estimates. Growth was primarily fueled by a 30.7% year-over-year increase in the Rare Disease segment and $17.7 million in revenue recognized through the Harmony out-licensing agreement. Despite the overall beat, the company narrowed its full-year guidance for its lead asset, Purified Cortrophin Gel, citing first-half results while maintaining its total company revenue and EBITDA outlook.
Key Highlights
- Revenue and Earnings Beat: Total net revenues rose 25.9% to $266.0 million, driven by Rare Disease momentum and the Harmony Agreement, which provided $9.7 million in royalties and $8.0 million in milestone payments.
- Cortrophin Gel Miss and Guidance Cut: While net revenues for Purified Cortrophin Gel grew 43.5% to $117.1 million, they fell short of the $124.0 million estimate. Consequently, FY2026 guidance for the product was lowered to $520M–$540M from the previous $540M–$575M.
- Gout Expansion Progress: The sales force expansion targeting acute gouty arthritis flares became fully operational in late June, with early indicators showing balanced demand across podiatry and primary care settings.
- Capital Allocation: The Board authorized a new $100.0 million share repurchase program effective May 8, 2026, running through May 2029.